Cholesstrinol HPe
Also known as: Cholesstrinol HP, Polymethoxylated Flavones and Tocotrienols Blend, Cholesstrinol HPe
Overview
Cholesstrinol HPe is a proprietary dietary supplement formulation designed for cardiovascular health, specifically targeting cholesterol management and inflammation reduction. It combines polymethoxylated flavones (PMFs) derived from citrus peels and tocotrienols, which are isoforms of vitamin E, typically extracted from palm oil. These compounds are recognized for their potent antioxidant and lipid-modulating properties. The supplement aims to improve cardiovascular health by reducing systemic inflammation, as indicated by lower levels of high-sensitivity C-reactive protein (hsCRP), and potentially by modulating lipid profiles. While preliminary clinical evidence from small open-label studies suggests benefits in reducing hsCRP in hypercholesterolemic adults, large-scale randomized controlled trials (RCTs) or meta-analyses specifically on Cholesstrinol HPe are currently lacking. The formulation is intended for adults seeking to manage cardiovascular risk factors.
Benefits
The primary reported benefit of Cholesstrinol HPe, or its similar predecessor Cholesstrinol HP, is the significant reduction of high-sensitivity C-reactive protein (hsCRP), a key marker of inflammation linked to cardiovascular risk. An open-label study involving 84 hypercholesterolemic adults over 12 weeks observed a notable decrease in hsCRP levels. This suggests a potential role in mitigating cardiovascular risk by addressing systemic inflammation. While the presence of tocotrienols and PMFs implies potential improvements in lipid profiles (cholesterol and triglycerides) due to their known mechanisms, direct evidence specifically for Cholesstrinol HPe's impact on lipid levels is limited. The benefits appear most relevant for adults with hypercholesterolemia and elevated cardiovascular risk markers. The strength of evidence is currently limited to a single open-label study, which lacks a control group and blinding, thus requiring further validation through more rigorous research.
How it works
Cholesstrinol HPe exerts its effects through the synergistic actions of its two main components: polymethoxylated flavones (PMFs) and tocotrienols. Both compounds possess strong antioxidant properties, helping to neutralize free radicals and reduce oxidative stress. They also inhibit inflammatory pathways, contributing to the observed reduction in systemic inflammation, particularly evidenced by lower hsCRP levels. Tocotrienols are known to modulate lipid metabolism, potentially inhibiting HMG-CoA reductase, an enzyme crucial for cholesterol synthesis, similar to statin drugs. PMFs also contribute to anti-inflammatory effects by modulating cytokine production. The combination aims to reduce systemic inflammation and potentially improve lipid profiles, thereby supporting overall cardiovascular health. The formulation is designed to optimize the absorption and bioavailability of these fat-soluble components.
Side effects
Based on the available research, no adverse events were reported in the cited open-label study involving Cholesstrinol HP. This suggests a generally favorable safety profile in the short term for the studied population. However, due to the limited scope and nature of the available studies (small, open-label, and without detailed safety reporting), comprehensive data on common, uncommon, or rare side effects are not available. There is a theoretical potential for interaction with cholesterol-lowering drugs, such as statins, due to overlapping mechanisms of action (e.g., HMG-CoA reductase inhibition by tocotrienols). While no specific drug interaction studies have been conducted, caution is advised when combining Cholesstrinol HPe with prescription medications, especially those affecting lipid metabolism. Contraindications have not been formally established. Furthermore, the safety of Cholesstrinol HPe in special populations, including pregnant or breastfeeding women, children, or individuals with severe pre-existing medical conditions, has not been studied, and its use in these groups should be approached with caution or avoided.
Dosage
Specific optimal dosage ranges for Cholesstrinol HPe are not clearly defined in the publicly available research, as it is a proprietary blend. The open-label study that reported benefits used a proprietary blend of Cholesstrinol HP over a 12-week period, but detailed dosing specifications were not provided. Therefore, a minimum effective dose, optimal dosage range, or maximum safe dose has not been established through independent research. As the components (PMFs and tocotrienols) are fat-soluble, it is generally recommended that such supplements be taken with a meal containing dietary fat to enhance absorption and bioavailability. The 12-week duration of supplementation in the study suggests that benefits may not be immediate and require consistent, long-term use. There are no specified required cofactors for its efficacy. Users should follow the manufacturer's recommended dosage on the product label, as this is a proprietary formulation.
FAQs
Is Cholesstrinol HPe effective for lowering cholesterol?
Direct evidence for Cholesstrinol HPe specifically lowering cholesterol is limited. While its components may influence lipid metabolism, the primary observed benefit in studies is a reduction in inflammation (hsCRP), a key cardiovascular risk marker, rather than direct cholesterol reduction.
Is it safe to take Cholesstrinol HPe with statins?
No direct interaction studies have been conducted with statins. Due to potential overlapping mechanisms on cholesterol pathways, caution is advised. Consult your healthcare provider before combining Cholesstrinol HPe with prescription medications.
How long does it take to see benefits from Cholesstrinol HPe?
Based on the available open-label study, benefits, specifically the reduction in hsCRP, were observed after 12 weeks of consistent supplementation. Individual results may vary, and long-term use may be necessary for sustained effects.
Does Cholesstrinol HPe replace prescription medications for heart health?
No, Cholesstrinol HPe is a dietary supplement and should not replace prescribed medications for heart health or cholesterol management. It is intended as a complementary supplement and should be used under the guidance of a healthcare professional.
Research Sources
- https://www.newhope.com/industry-insights/source-one-s-cholesstrinol-hp-cuts-inflammation-in-study – This article reports on an open-label clinical study involving 84 hypercholesterolemic adults who took Cholesstrinol HP for 12 weeks. The study found a significant reduction in hsCRP, an inflammation marker linked to cardiovascular risk. However, the study had limitations, including a lack of a control group, no blinding, and no detailed statistical data provided in the summary.
- https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/cholesterol-and-triglyceride-levels-in-firstepisode-psychosis-systematic-review-and-metaanalysis/D4103333519B764F7D80314BF6939AC2 – This source is a systematic review and meta-analysis focusing on cholesterol and triglyceride levels in first-episode psychosis. While it discusses lipid markers, it does not evaluate Cholesstrinol HPe or similar proprietary blends, indicating that specific research on this formulation is not included in broader meta-analyses on lipid outcomes.
- https://pubmed.ncbi.nlm.nih.gov/32430016/ – This PubMed entry likely refers to a study or review related to cholesterol or inflammation markers. However, it does not specifically evaluate Cholesstrinol HPe or similar proprietary blends, reinforcing the observation that high-quality, independent research on this specific formulation is scarce in major scientific databases.
- https://www.nutraceuticalsworld.com/breaking-news/cholesstrinol-hp-hpe-double-strength-heart-health-formulas/ – This article from Nutraceuticals World discusses Cholesstrinol HP and HPe as double-strength heart health formulas. It provides industry insights and marketing information about the products but does not present new, independent clinical trial data or detailed scientific findings beyond what is reported by the manufacturer or in the initial open-label study.
- https://pubmed.ncbi.nlm.nih.gov/36751516/ – This PubMed entry, similar to the other, likely pertains to research on cholesterol or inflammation. However, it does not specifically evaluate Cholesstrinol HPe or similar proprietary blends, further indicating the absence of direct, high-quality research on this specific formulation in major scientific literature databases.
